Galidesivir hydrochloride (C09-1135-655)

Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV , and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC 50 s ranging from ~3 to ~68 μMIn VitroCellular kinases phosphorylate Galidesivir (BCX4430) hydrochloride to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination. ?/nGalidesivir hydrochloride effectively inhibits the infection of Vero cells with YFV. The EC 50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoGalidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir hydrochloride has demonstrated pronounced efficacy . ?/nGalidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Syrian golden hamsters (hamsters infected with YF virus)Dosage: 4 mg/kg of body weight Administration: I.p.; twice daily for 7 days Result: Significantly improved the survival of hamsters infected with YFV.Form:SolidIC50& Target:RdRp inhibitor. Specification: 0.99 Molecular Formula: C11H16ClN5O3 Molecular Weight: 301.73 PubChem CID: 69211190 Isomeric SMILES: C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl